Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-04
Application #
8543577
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Nothwehr, Steven F
Project Start
2010-09-22
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2013
Total Cost
$2,150,500
Indirect Cost
$688,644
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Hong, Bangxing; Li, Haiyan; Zhang, Mingjun et al. (2015) p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136:34-43
Shi, Qiuling; Wang, Xin Shelley; Li, Guojun et al. (2015) Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:1138-46
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56:1335-41
Parmar, S; Kongtim, P; Champlin, R et al. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49:1036-41
Chen, Zheng; Orlowski, Robert Z; Wang, Michael et al. (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204-8
San-Miguel, Jesús; Bladé, Joan; Shpilberg, Ofer et al. (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136-42
Srkalovic, Gordan; Hussein, Mohamad A; Hoering, Antje et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3:1275-83
Ocio, Enrique M; Mitsiades, Constantine S; Orlowski, Robert Z et al. (2014) Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-41

Showing the most recent 10 out of 79 publications